When delivered orally for 4 weeks, this peptide-based immunotherapy induced Tregs and ovomucoid-specific IgA, while reducing ovomucoid-specific IgE, ultimately preventing anaphylaxis (40). This evidence concerns the gene IGHE and anaphylaxis.